A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Recruiting

Phase 1

Phase 2

Gilteritinib, Venetoclax, AzacitidineA Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Sponsor:

Astellas Pharma Global Development, Inc.

Code:

NCT05520567

Conditions

Acute Myeloid Leukemia (AML)

FLT3-mutated Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Gilteritinib

Venetoclax

Azacitidine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-29. This information was provided to ClinicalTrials.gov by Astellas Pharma Global Development, Inc. on 2025-11-03.